Anavex Life Sciences Corp (AVXL)

[Kentucky123]

Verbiage "The $XBI outperformed all sectors incl the NASDAQ from its 06 launch to Feb 21 peak. The reasons since are multi-fold but primarily due to too many IPOs at rich valuations coupled with the FDA making it more difficult/time consuming to get a product to market (which may be good or bad).

Smaller-cap biotechs with FDA approved products that trade for below cash may, eventually, trade up to market caps consistent with historical valuations. Before Feb. 21 it was considered practically "impossible" for bio/pharma stocks, even with only an IND, could trade for less than cash like $EIGR, $AADI, $ENTA (incl. royalty sales). Of course mgmt may share some fault/blame but look at the graph. "

In 3/23 Baron's published an article essentially saying it may (emphasis on may) be time for investors to jump back into bio/pharma. Considering the delta (in red) btwn the XBI & XLT, there's room to grow. Whether it happens is another matter.

As always, we could be wrong.